Profile cover photo
Profile photo
Gyros AB
15 followers -
Biopharma Productivity Revolutionized
Biopharma Productivity Revolutionized

15 followers
About
Gyros AB's posts

Post has attachment
Free Gyrolab Webinar Invitation
Automated nanoliter-scale immunoassays to maximize productivity in bioprocess development
Tuesday 26th April 2016
Time: 14:00 UK BST / 15:00 CET
Register on:
http://www.workcast.com/register?cpak=3828223756275314

Post has attachment
http://www.gyros.com/news/gyros-ab-protein-technologies-merge-form-gyros-protein-technologies-ab

Uppsala, Sweden and Tucson, AZ, 16 March 2016: Gyros AB, a pioneer in automated nanoliter-scale immunoassays, and Protein Technologies, Inc., a leading provider of peptide synthesis instrumentation and reagents, today announced the companies have entered into a definitive merger agreement, to form Gyros Protein Technologies AB (the “Company”). The merger is expected to be completed within the next 30 days and is subject to certain closing conditions. 

Post has attachment
http://www.gyros.com/GLS

We are pleased to announce and formally invite you to the 2016 European Gyrolab Seminar in Amsterdam, Monday June 13 to Tuesday June 14.

This year the Gyrolab Seminar hosts independent speakers from the biotherapeutic industry, presenting the latest papers, applications and advances using Gyrolab nanoliter-scale immunoassay technology. Attendees are a mix of existing users and those who simply wish to find out more about Gyros and immunoassay advances. Network with others within CRO, CMO, Pharmaceutical, Biotech and Academic organizations.

Post has attachment
http://hubs.ly/H01Z8_B0

ADME of therapeutic proteins

Review of critical factors, analytical methods and experimental approaches

Therapeutic proteins have revolutionized the treatment of many diseases and have a promising future with more than forty monoclonal antibodies and Fc-fusion therapeutics already on the US market and over 400 more in clinical development stages. Therapeutic proteins are, however, hit hard by a high attrition rate, mainly to poor efficacy, which results in only one in ten making it to market. Increasing the success rate relies on many factors, including the study of absorption, distribution, metabolism and excretion (ADME), as Jay Tibbitts at UCB Celltech, UK, and his coauthors point out in their extensive review on the subject.

Post has attachment

Post has attachment

Post has attachment
http://hubs.ly/H01cdfS0

We are pleased to announce and formally invite you to the 2015 Gyrolab Seminar from Wednesday, October 14  to Thursday, October 15.

This year the Gyrolab Seminar will host over a dozen independent speakers from the biotherapeutic community, presenting the latest papers, applications and advances using Gyrolab nanoliter-scale immunoassay technology in broadening bioanalysis capabilities in capacity, dynamic range, time to results and automation using only nanoliter volumes.

Overview
• Free workshop to advance your Gyrolab method development
• Live demos of Gyrolab technology
• User presentations covering PK, PK, ADA and bioprocess
• EMD Millipore custom GyroMark kits with 2 week turn-around

Attendees are a global mix of existing users and those who simply wish to find out more about Gyros and immunoassay advances in discovery, bioprocess, preclinical and clinical devleopment. Network with others within CRO, Pharmaceutical, Biotech and Academic organizations.
Photo

Live demonstration of Gyrolab xPlore at Bio ANALYTICAL FORMULATION

Visit us at booth # 17 - Bio ANALYTICAL FORMULATION, Berlin Sept. 15-16 to learn more about our instrument Gyrolab xPlore™ - the single-CD, cost-effective system making automated nanoliter-scale immunoassays accessible to laboratories of every size.

Listen to E. Escoffier at Bio ANALYTICAL FORMULATION, Berlin September 15

Emelie Escoffier, Sr. Research Assistant, NovImmune SA will present her work on  “Challenges in the development of clinical PK, PD and ADA assays on the Gyrolab™ automated microfluidics platform”
Tuesday September 15 | time: 12:15

Post has attachment
http://hubs.ly/H018cKG0

ADC + LBA = True

The value and challenges in using ligand-binding assays to analyze Antibody-Drug Conjugates

Antibody-Drug Conjugates (ADCs) offer great potential in directing therapeutic agents directly to the target, but the complexity of their structure and dynamics in vivo present many bioanalytical challenges. In a recent review article, Seema Kumar and her colleagues at Pfizer Global R&D in the USA present a comprehensive analysis of how Ligand Binding Assays (LBAs) can be used in ADC analysis in preclinical studies.
Wait while more posts are being loaded